FDA approves Zulresso for use in treatment of postpartum depression

today,the FDA's(http://announced that it has approved the listing of, adevelopment by SAGE Therapeuticshttp://
, to treat patients with postpartum depression (PPD)this therapy will be injected by qualified health care providers inMedical(http://institutions that have undergone risk assessment and remission strategy certification (REMS)Zulresso became the first approved treatment for PPD, and the first FDA-approved treatment by SAGEAbout Zulresso
Zulresso is an other-constructing regulator for GABAA receptors that regulatethe function of gabaA a receptor within and outside the synapseThe other configuration regulation of the neurotransmitter receptor can regulate the receptor activity to different levels, rather than fully activating or suppressing the receptorGABAA receptors and NMDA receptors act as inhibiting and stimulating nerve impulses in brain neurons, respectively The imbalance between these two receptor strains is the cause of a variety of mental illnesses such as depression Zulresso effectively and safely restores the balance between GABAA receptor and NMDA receptor activity Zulresso has been awarded the
of the BREAKTHROUGH Therapy by the FDA and the HTTP://WWW.CHEMDRUG.COM/ of the PRIME Medicines
awarded by the EMA 　　About Hummingbird This approval is based on a clinical trial (http:// program called Hummingbird, which includes three multicenter, randomized double-blind clinical trials with placebo control In two Phase 3 clinical trials called Study 202B and Study 202C, Zulresso reached the main endpoint of both trials, and after 60 hours of treatment, the patient's Hamilton Depression Scale (HAM-D) score decreased significantly more than the baseline group The total HAM-D score of patients treated with Zulresso decreased by an average of 14-20 points and lasted up to 30 days